HC Wainwright Has Bearish Estimate for EYPT Q3 Earnings

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Eyepoint Pharmaceuticals in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.60) for the quarter, down from their previous estimate of ($0.48). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($3.15) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.84) EPS.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%.

Several other equities analysts also recently commented on EYPT. Guggenheim restated a “buy” rating and issued a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald lifted their price objective on shares of Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. Royal Bank Of Canada decreased their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $65.00 target price on shares of Eyepoint Pharmaceuticals in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.38.

Eyepoint Pharmaceuticals Stock Performance

EYPT opened at $13.05 on Monday. Eyepoint Pharmaceuticals has a fifty-two week low of $9.65 and a fifty-two week high of $19.11. The company has a market capitalization of $1.13 billion, a P/E ratio of -3.49 and a beta of 1.76. The stock has a fifty day moving average of $13.12 and a 200-day moving average of $13.73.

Institutional Trading of Eyepoint Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Stempoint Capital LP increased its position in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares during the period. Janus Henderson Group PLC lifted its position in Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the period. California State Teachers Retirement System lifted its position in Eyepoint Pharmaceuticals by 2,158.3% during the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after purchasing an additional 100,447 shares during the period. The Manufacturers Life Insurance Company grew its stake in Eyepoint Pharmaceuticals by 58.4% during the first quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock worth $465,000 after buying an additional 13,297 shares in the last quarter. Finally, Commodore Capital LP acquired a new stake in Eyepoint Pharmaceuticals during the first quarter worth about $36,414,000. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.